NEXTBIOMEDICAL Secures the US FDA’s IDE Approval of Nexsphere-F to Use it in Genicular Artery Embolization (GAE) for Knee Osteoarthritis
Shots:
- The US FDA has granted IDE approval to initiate RESORB clinical evaluation of Nexsphere-F for knee osteoarthritis. It is CE-MDD approved for arthritis embolization & has shown superior efficacy in various musculoskeletal embolization cases across Asia & the EU
- RESORB study will evaluate the efficacy of Nexsphere-F to ease pain & improve mobility in knee osteoarthritis patients, to be recruited in leading healthcare institutions across the US
- Nexsphere-F is a fast-resorbable hydrophilic microsphere, injected with a contrast medium, for endovascular embolization. It swells to temporarily block target blood vessels for promoting therapeutic outcomes & are fully resorbed to ensure biocompatibility
Ref: Prnewswire | Image: NEXTBIOMEDICAL
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
